1. Home
  2. VTYX vs UPBD Comparison

VTYX vs UPBD Comparison

Compare VTYX & UPBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$13.98

Market Cap

990.9M

Sector

Health Care

ML Signal

HOLD

Logo Upbound Group Inc.

UPBD

Upbound Group Inc.

HOLD

Current Price

$19.33

Market Cap

1.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTYX
UPBD
Founded
2018
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
990.9M
1.2B
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
VTYX
UPBD
Price
$13.98
$19.33
Analyst Decision
Hold
Strong Buy
Analyst Count
7
4
Target Price
$13.50
$32.25
AVG Volume (30 Days)
5.9M
656.9K
Earning Date
02-26-2026
02-19-2026
Dividend Yield
N/A
8.09%
EPS Growth
N/A
N/A
EPS
N/A
1.45
Revenue
N/A
$4,577,844,000.00
Revenue This Year
N/A
$10.38
Revenue Next Year
N/A
$7.40
P/E Ratio
N/A
$13.29
Revenue Growth
N/A
7.48
52 Week Low
$0.78
$15.82
52 Week High
$25.00
$30.62

Technical Indicators

Market Signals
Indicator
VTYX
UPBD
Relative Strength Index (RSI) 75.73 55.73
Support Level $7.08 $18.96
Resistance Level $14.07 $20.28
Average True Range (ATR) 0.27 0.88
MACD 0.06 0.04
Stochastic Oscillator 83.47 71.01

Price Performance

Historical Comparison
VTYX
UPBD

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

Share on Social Networks: